Needle-free injection technology PharmaJet reported on Tuesday the launch of a needle-free injection trial partnership with Vaccibody AS.

As part of the partnership, Vaccibody AS is expanding its human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis' needle-free injection system. The Stratis Injector has US FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use and eliminate needlestick injuries.

Nearly all cervical cancer is caused by high risk Human papillomavirus (HPV), with an estimated 530,000 new cases and 275,000 deaths annually, the leading cause of cancer deaths in women. An additional 10m women are impacted by a long pre-invasive disease called Cervical Intraepithelial Neoplasia (CIN).

Last year, Vaccibody reported successful clinical trial results of its therapeutic DNA vaccine (VB10.16) delivered with PharmaJet's needle-free injection technology. The vaccine had an excellent safety profile and induced the strongest HPV16-specific immune response that has been reported in literature.

Following the successful trial, the recruitment has now been finalised for Vaccibody AS' phase IIa human clinical trial.